Brief: Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted To AT-752 For Treatment Of Dengue
26/09/2022 12:04
Sept 26 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS ANNOUNCES U.S. FDA FAST TRACK
DESIGNATION
GRANTED TO AT-752 FOR TREATMENT OF DENGUE
* ATEA PHARMACEUTICALS INC - AT-752 IS A NOVEL, ORALLY
ADMINISTERED, DIRECT-ACTING ANTIVIRAL IN PHASE 2 DEVELOPMENT FOR
TREATMENT OF DENGUE
* ATEA - AT-752 IS SHOWING POTENT IN VITRO AND IN VIVO
ACTIVITY IN
PRECLINICAL STUDIES AND FAVORABLE SAFETY AND TOLERABILITY IN
PHASE 1 TRIAL
Source text for Eikon: ID:nGNX3YZgwC
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM